These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1826438)

  • 1. Treatment of bone metastases from breast cancer and myeloma with pamidronate.
    Thiébaud D; Leyvraz S; von Fliedner V; Perey L; Cornu P; Thiébaud S; Burckhardt P
    Eur J Cancer; 1991; 27(1):37-41. PubMed ID: 1826438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
    Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
    Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Disodium pamidronate (APD) in the treatment of bone metastases].
    Costa L; Moreira C; da Costa EB
    Acta Med Port; 1993 Feb; 6(2):71-3. PubMed ID: 8488764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of pamidronate in patients with metastatic bone disease.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    Br J Cancer; 1996 May; 73(9):1089-95. PubMed ID: 8624269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
    Tyrrell CJ
    Ann Oncol; 1994; 5 Suppl 7():S37-40. PubMed ID: 7532992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
    Kokufu I; Taniguchi H; Kim YH; Fukuda K; Yamamoto M; Yano T; Yamada K; Kitano H
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1751-4. PubMed ID: 11057329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disodium pamidronate in the treatment of bone metastases from breast cancer.
    Colleoni M; Bochicchio AM; Nolè F; Bajetta E
    Tumori; 1993 Oct; 79(5):340-2. PubMed ID: 8116078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
    Dodwell DJ; Howell A; Ford J
    Br J Cancer; 1990 Jan; 61(1):123-5. PubMed ID: 2297483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
    Vinholes JJ; Purohit OP; Abbey ME; Eastell R; Coleman RE
    Ann Oncol; 1997 Dec; 8(12):1243-50. PubMed ID: 9496390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
    Coleman RE; Houston S; Purohit OP; Rubens RD; Kandra A; Ford J
    Eur J Cancer; 1998 May; 34(6):820-4. PubMed ID: 9797692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases].
    Senkus-Konefka E; Krasińska L; Pikiel J; Krasińska W; Nowaczyk M; Jassem J
    Przegl Lek; 2003; 60(7):467-70. PubMed ID: 14750420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
    Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
    Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.